侧脑室注射Orexins对大鼠摄食的影响及机制

目的:探讨侧脑室注射orexins(食欲素)、NPY(神经肽Y)、MCH(黑色素聚集激素)和甘丙肽对大鼠摄食的影响及其机制。方法:将成年雄性Wistar大鼠随机分为对照组、侧脑室注射组和室旁核(PVN)注射组。通过套管将orexin-A、orexin-B、NPY、MCH和甘丙肽分别注射至侧脑室和PVN内,随后测量大鼠食物摄入量,并检测PVN、弓状核(ARC)和VMH内c-fos的表达。结果:与对照组比较,侧脑室注射NPY、MCH和orexin-B 2 h后,大鼠摄食量显著增多(P0.05)。相较于orexin-B和MCH,NPY对摄食的影响更显著(P0.05)。与NS对照组比较,侧脑室注射甘丙肽和orexin-A 1 h后,大鼠摄食量显著增多(P0.05)。与NS对照组比较,侧脑室注射orexin-A可显著增加c-fos在PVN和ARC中的表达,在VMH中效应较弱(P0.05)。与NS对照组比较,PVN注射NPY能显著增加大鼠2 h摄食量(P0.05),PVN注射orexin-A能显著增加大鼠2 h和4 h摄食量(P0.05)。结论:orexins与可促进大鼠摄食,此效应可能通过下丘脑参与摄食调控中枢PVN和ARC而实现的。     

下丘脑室旁核orexin-A对大鼠摄食和胃动力影响及调控机制

目的:探讨下丘脑室旁核orexin-A对大鼠摄食和胃动力影响及调控机制。方法:采用免疫组化观察下丘脑室旁核(paraventricular nucleus,PVN)orexin受体表达情况;PVN注射orexin-A观察大鼠摄食、胃运动、胃酸分泌和胃排空的改变。结果:免疫组化实验显示大鼠PVN中存在orexin受体免疫阳性细胞。PVN注射orexin-A后,大鼠前三小时摄食增加,6 h和24 h摄食无显著改变。PVN微量注射orexin-A后,大鼠胃运动幅度和频率增加、胃排空增快并且胃酸分泌增多。[D-Lys-3]-GHRP-6可部分阻断orexin-A对摄食、胃运动、胃排空和胃酸分泌的促进作用,SB334867可完全阻断orexin-A对胃运动、胃排空和胃酸分泌的促进作用。结论:下丘脑室旁核orexin-A可能通过生长激素促泌素GHSR受体信号通路调控大鼠摄食及胃功能。     

Orexin-A通路对胃运动的调控研究

目的:探讨下丘脑外侧核(LHA)-伏隔核(NAcc)orexin-A神经和功能通路构成及该通路对胃运动的影响及潜在机制。方法:将健康成年雄性Wistar大鼠随机分为逆行追踪组和胃运动组:逆行追踪组大鼠采用逆行追踪技术结合免疫荧光组织化学染色法,观察下丘脑外侧核-伏隔核间是否存在orexin-A神经通路;胃运动组大鼠通过在体胃运动研究,观察伏隔核内微量注射不同浓度orexin-A对大鼠胃运动幅度和频率的影响,以及电刺激下丘脑外侧核后,大鼠胃运动的变化及机制。结果:荧光逆行追踪结合荧光免疫组织化学染色结果显示:下丘脑外侧核内有荧光金和orexin-A双重标记的神经元。胃运动研究结果显示:伏隔核内微量注射orexin-A,大鼠胃运动幅度和频率显著增加,并呈现显著剂量依赖关系(P0.05),伏隔核预先微量注射SB-334867,可反转该效应(P0.05)。电刺激下丘脑外侧核,大鼠胃运动幅度和频率显著增强(P0.05)。同样,伏隔核内微量注射SB-334867,再电刺激下丘脑外侧核,电刺激导致的胃运动增强效应显著减弱(P0.05)。结论:下丘脑外侧核-伏隔核存在orexin-A神经和功能通路,该通路可能通过orexin-A受体介导参与胃动力和能量代谢调控。     

侧脑室注射orexin-A对大鼠昼夜摄食的影响

目的:探讨侧脑室注射orexin-A对大鼠昼夜摄食的影响。方法:将Wistar大鼠随机分组,采用单剂量侧脑室注射和连续侧脑室注射以及外周注射法,分别于日间和夜间给药,测量大鼠24小时内各阶段的摄食量以及相应生化指标。结果:在光照期间,侧脑室微量注射orexin-A,大鼠4小时内摄食量显著增加(P0.05),且呈剂量依赖关系(P0.05)。在夜间初期(18:00)侧脑室注射orexin-A,大鼠食物摄入量无显著差异(P0.05)。但在中午12:00给予侧脑室注射orexin-A,注射后4小时内大鼠摄食量显著高于NS对照组(P0.05)。连续8日给予orexin-A侧脑室注射,可使注射后日间摄食量显著增加(P0.05),而夜间摄食量显著减少(P0.05),但24小时内总的摄食量不变(P0.05)。orexin-A并未改变棕色脂肪组织温度、末梢血糖、血浆瘦素等指标的水平。结论:orexin-A对大鼠摄食的调节具有昼夜节律性。     

Orexin能神经元在依托咪脂麻醉中的促觉醒作用

目的:观察orexin能神经元在依托咪脂麻醉中的促觉醒作用。方法:选择雄性SD大鼠36只,体重230～250g。将18只SD大鼠随机分为脂肪乳剂组(60 mg·kg~(-1)·h~(-1)),依托咪脂麻醉(50 mg·kg~(-1)·h~(-1))30 min组和60 min组(每组n=6),用放射免疫法检测3组大鼠血浆中orexin含量;3天后,将脂肪乳剂组大鼠颈椎脱臼处死后灌注取脑,另外两组在依托咪脂麻醉下灌注取脑,采用免疫荧光双标染色,分别观察3组大鼠orexin神经元活性。另取18只SD大鼠随机分为乳酸林格氏液组,orexin-A 30 pmol组和100pmol组(每组n=6),记录大鼠翻正反射消失时间为麻醉诱导时间及翻正反射恢复时间为觉醒时间。结果:与脂肪乳剂组相比,依托咪脂麻醉30 min和60 min后,血浆orexin-A含量下降(P0.05),有活性的orexin神经元数目减少(P0.01);与依托咪脂麻醉30 min组相比,60 min组有活性的orexin神经元数目减少(P0.05),但血浆orexin-A含量与30 min组无差异(P0.05);与乳酸林格氏溶液组相比,基底前脑区微注射orexin-A 30 pmol或100 pmol对麻醉诱导无影响,但能显著缩短依托咪脂麻醉觉醒时间(P0.05,P0.01);但orexin-A 30 pmol组和100 pmol组诱导和觉醒时间比较均无统计学差异(P0.05)。结论:依托咪脂麻醉抑制大鼠下丘脑orexin神经元的活性,orexin-A对依托咪脂麻醉具有促觉醒作用。     

第四脑室注射orexin-A及OX1R拮抗剂对大鼠摄食及自由活动的影响

本文旨在探讨第四脑室注射orexin-A及orexin 1型受体(orexin-1 receptor,OX1R)拮抗剂SB334867对肥胖和正常大鼠摄食和自由活动的影响。采用高脂饲料诱导建立肥胖大鼠模型,分别在肥胖和正常大鼠第四脑室注射不同剂量orexin-A或SB334867,观察光照和黑暗环境下两种大鼠0~4 h摄食量及活动量的变化。结果显示,第四脑室注射不同剂量orexin-A,光照条件下,正常和肥胖大鼠0~4 h摄食量和活动量均较生理盐水对照组明显增加,呈剂量依赖关系(P0.05~0.01);且肥胖大鼠摄食量和活动量显著高于正常大鼠;黑暗条件下,不同剂量的orexin-A对正常和肥胖大鼠摄食量和活动量均没有明显改变(P0.05)。第四脑室注射不同剂量SB334867,光照条件下,正常和肥胖大鼠0~2 h,2~4 h摄食量和活动量均较生理盐水对照组明显减少(P0.05);且肥胖大鼠摄食量和活动量均显著高于正常大鼠;黑暗条件下,正常和肥胖大鼠摄食量和活动量均没有明显改变(P0.05)。以上结果提示,第四脑室周核团可能是orexin-A及OX1R作用靶点之一;光照条件对orexin-A和OX1R生理功能的发挥可能具有重要影响。     

Orexin-A介导histamine能神经系统促进氯胺酮麻醉觉醒

目的:探索氯胺酮麻醉下,Orexin神经信号是否激活结节乳头体核(Tuberomammillary Nucleus,TMN)促进大鼠氯胺酮麻醉觉醒。方法:成年雄性SD大鼠(体重230-280 g),在10%水合氯醛麻醉下(1 ml/kg,i.p.)进行以下实验:1TMN核团埋置微注射外套管,回笼单独饲养7天后,大鼠随机分为三组,分别为对照组(NS)、orexin-A组与orexin-B组。TMN核团分别双侧微注射NS(0.3μL)、orexin-A(100 pmol/0.3μL)及orexin-B(100 pmol/0.3μL)观察氯胺酮麻醉下(100 mg/kg,腹腔注射)大鼠诱导时间与觉醒时间;2上述实验7天后,大鼠随机分为三组,分别为溶剂DMSO组、SB334867组与TCS-OX2-29组,TMN核团分别双侧微注射DMSO(0.3μL)、orexin 1型受体(the orexin type 1 receptor,OX1R)的拮抗剂SB334867(20μg/0.3μL)和orexin 2型受体(the orexin type 2 receptor,OX2R)的拮抗剂TCS-OX2-29(20μg/0.3μL)观察氯胺酮麻醉下大鼠诱导时间与觉醒时间。结果:1各组大鼠的诱导时间无统计学差异。2在TMN核团微注射orexin-A与对照组相比明显缩短了大鼠的觉醒时间(43.17±6.31 min vs51.17±4.45 min,P0.05),而微注射orexin-B与对照组相比并没有明显影响大鼠的觉醒时间(50.33±3.50 min vs 51.17±4.45min,P0.05)。3TMN核团微注射OX1R拮抗剂SB334867较溶剂DMSO组延长了麻醉觉醒时间(60.83±8.84 min vs 49.00±5.73 min,P0.05),OX2R拮抗剂TCS-OX2-29与溶剂DMSO组相比并没有明显影响大鼠的觉醒时间(50.83±4.79 min vs 49.00±5.73 min,P0.05)。结论:本研究实验证据证实在氯胺酮麻醉下,orexin神经信号可能通过激活TMN区组胺能神经系统促进麻醉向觉醒的转换。     

大鼠室旁核注射orexin-A对体重的影响

目的:探讨大鼠室旁核(PVN)注射orexin-A对体重的影响。方法:大鼠室旁核(PVN)微量注射orexin-A,用大脑置管埋管、组织化学染色等方法探讨PVN注射orexin-A对其体重的影响。结果:与安慰剂组大鼠相比,PVN注射orexin-A组大鼠体重明显减轻(P0.05),而orexin-A组和安慰剂组摄食量无明显差异(P0.05)。注射结束后6天,orexin-A处理大鼠的体重仍显著低于注射前(P0.05),而安慰剂组大鼠则比注射前显著增重(P0.05)。药物注射可显著降低机体脂肪,但并不特异存在于注射orexin-A或安慰剂的大鼠身上。Orexin-A组和安慰剂组大鼠的肌肉量和脂肪量均显著降低(P0.05),但注射orexin-A的大鼠降低更明显。与安慰剂组相比,orexin-A处理后的摄食转化率显著降低(P0.05)。结论:大鼠室旁核(PVN)注射orexin-A可通过增加活动量产生负能量平衡,引起体重减轻。     

大鼠延髓背侧迷走复合体注射ghrelin激活弓状核神经肽Y/刺鼠色蛋白相关蛋白神经元而诱发多食(英文)

Ghrelin是生长素促分泌受体的内源性配体,刺激摄食并增加体重。已有研究证实ghrelin刺激摄食的作用靶点主要是下丘脑弓状核(hypothalamic arcuate nucleus,ARC)内的神经肽Y(neuropeptide Y,NPY)/刺鼠色蛋白相关蛋白(agouti-related peptide,AgRP)神经元。除下丘脑外,脑干尾部迷走复合体具有ghrelin受体,是ghrelin调控摄食活动的另一靶点。本实验旨在验证ghrelin作用于脑干尾部所诱发的摄食增加是否需要下丘脑NPY/AgRP神经元参与。在大鼠延髓背侧迷走复合体(dorsal vagalcomplex,DVC)微量注射20pmol的ghrelin,用摄食自动分析仪测量大鼠的摄食反应,用荧光定量PCR技术测定ARC的NPY/AgRP mRNA的表达水平,同时利用免疫组化技术测定ARC的NPY阳性神经元数量及光密度。结果显示,与对照组(DVC微量注射生理盐水)相比,ghrelin微注射组大鼠摄食量增加,其累积摄食量在注射后2h达最高峰;ARC处NPY/AgRP mRNA的表达水平、NPY免疫阳性神经元的数量及光密度也明显增加,且均在ghrelin注射后2h增高达到高峰。以上结果提示,大鼠DVC注射ghrelin可能通过上行纤维激活弓状核NPY/AgRP神经元,介导大鼠的多食反应。     

中枢注射Nesfatin-1与Exendin(9-39)对大鼠摄食和胃肠动力调节的影响

目的:探讨下丘脑室旁核注射GLP-1R拮抗剂Exendin(9-39)对Nesfatin-1所致大鼠摄食和胃肠动力改变的影响及作用机制。方法:选择40只雄性Wistar大鼠,随机分成正常对照组(NC组)、Nesfatin-1组(NS组)、Exendin(9-39)组(ES组)、Nesfatin-1联合Exendin(9-39)组(NE组)。采用下丘脑室旁核(PVN)埋置套管并分别给予以上药物干预,干预前和干预后的12小时、24小时记录和比较各组大鼠的摄食、饮水及体重变化。2天后,采用甲基纤维素-酚红溶液灌胃法测各组大鼠胃排空率,实时荧光定量法(RT-PCR)检测下丘脑及胃组织GLP-1Rm RNA的表达。结果:与基础摄食量比较,NS组大鼠给药后12 h、24 h的摄食量减少(P0.05),NE组大鼠给药后12 h、24 h的摄食量减少(P0.05),但较NS组增加(P0.05);与基础饮水量比较,NS组、NE组给药后12 h饮水量减少(P0.05);与基础体重比较,NS组大鼠给药后12 h、24 h的体重降低(P0.05),NE组大鼠给药后12 h的体重降低(P0.05),但较NS组增加(P0.05);NS组大鼠给药后胃排空率较NC、NE组大鼠显著下降(P0.05),NS组大鼠下丘脑GLP-1Rm RNA的表达量较NC组增加(P0.05)。结论:中枢给予GLP-1R拮抗剂能减弱Nesfatin-1引起的摄食抑制、胃排空延迟及体重下降效应,Nesfatin-1可能通过与GLP-1的协同作用参与摄食及胃肠动力的调节。     

Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.

The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats. Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors). Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity. Systemic cocaine (10 mg/kg) significantly increased the locomotor activity of rats. GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity. Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core. When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist. The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side). Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively. In other words, the present results suggest that the accumbal shell 5-HT1B receptors play a permissive role in the behavioural response to the psychostimulant.     

Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior

Amylin, a calcitonin gene-related peptide-like peptide coreleased with insulin, exerts anorexic effects on central administration. Because previous studies revealed dense amylin binding in the nucleus accumbens (Acb), we investigated the behavioral effects of amylin infusions (10, 30, and 100 ng/side) into Acb subregions. Intra-Acb shell amylin infusions decreased ambulation, rearing, feeding, and drinking in either food-deprived rats or water-deprived rats; motor activity was affected more potently than ingestive behavior. Moreover, intra-Acb shell amylin reduced motor activity in nondeprived rats tested in the absence of food or water, indicating that the expression of amylin's effects is independent of drive or proximal incentives. Intra-Acb core amylin infusions in water-deprived rats also decreased ambulation and water intake, although anterior Acb placements were associated with smaller motor effects, regardless of Acb subregion. In contrast to amylin's effects, intra-Acb shell infusions of orexin-A (50, 100, and 500 ng/side) had no effects on motor activity, feeding, or drinking. Hence the Acb may be a target for behavioral regulation by satiety-related peptides like amylin.     

Orexin-induced feeding requires NMDA receptor activation in the perifornical region of the lateral hypothalamus

Food intake is stimulated following administration of orexin-A into the perifornical region of the lateral hypothalamus (LH/PFA). Orexin neurons originating in the LH/PFA interact with a number of hypothalamic systems known to influence food intake, including glutamatergic neurons. Glutamatergic systems in the LH/PFA were demonstrated to initiate feeding through N-methyl-d-aspartic acid (NMDA) receptors. Male Sprague-Dawley rats fitted with brain guide cannulas to the LH/PFA were used in two experiments. In the first experiment, a combination microdialysis/microinjection probe was used to deliver artificial cerebrospinal fluid (aCSF) or 500 pmol of orexin-A into the LH/PFA. Orexin-A increased interstitial glutamate to 143 +/- 12% of baseline (P < 0.05), which remained elevated over the 120-min collection period. In the second experiment, the NMDA receptor antagonist d-2-amino-5-phosphonopentanoic acid (d-AP5; 10 nmol) was administered before orexin-A. The orexin-induced increase in food intake (from 1.1 +/- 0.4 to 3.2 +/- 0.5 g, P < 0.05) during the first hour was absent in rats receiving d-AP5 + orexin-A (1.2 +/- 0.5 g). There was no effect of d-AP5 alone on food intake. These data support glutamatergic systems in the LH/PFA mediating the feeding response to orexin-A through NMDA receptors.     

The Stimulatory Effect of Cerebral Intraventricular Injection of cNPY on Precocial Feeding Behavior in Neonatal Chicks (Gallus domesticus)

Neuropeptide Y (NPY) is one of the most potent stimulants of food intake in many animals. Most of the supporting evidence for the effects of NPY has been gathered in mammalian species using porcine NPY. To investigate the effects of NPY on precocial feeding initiation in chicks, we firstly used chicken NPY (cNPY) to study its role in food intake and spontaneous activities in 3-day-old male chicks. Food intake was monitored at different times after intracerebroventricular (ICV) injection of cNPY (2.5, 5.0 or 10.0 μg/10 μL) and anti-cNPY antibody (anti-cNPY) (1:9000, 1:3000 or 1:1000 in dilution). cNPY given at different doses significantly increased food intake at 30 min, 60 min, 90 min and 120 min after injection. Chicks treated with 5.0 μg/10 μL of cNPY showed a maximal 4.48 fold increase in food intake comparing to the control at 30 min. There is still more than 2 fold increase in food intake at 120 min after injection of cNPY. Food intake was significantly inhibited by a single ICV injection of anti-cNPY diluted to 1:9000 (60% inhibition), 1:3000 (92% inhibition), and 1:1000 (95% inhibition) at 30 min with 1:1000 being the maximally effective concentration. The inhibitory effects of anti-cNPY (diluted to1:9000, 1:3000, 1:1000) at 120 min post ICV injection were 22%, 42% and 46%, respectively. But ICV of anti-cNPY (1:3000 in dilution) did not block the orexigenic effect of 2.5 μg/10 μL of cNPY. ICV injection of different concentrations of cNPY increases locomotor activity in a dose-dependent manner while ICV anti-cNPY greatly decreased the distance moved by each chick compared to control groups. Taken together, our results demonstrated that cNPY has a promoting effect on chick food intake and locomotor activity, and that endogenous cNPY might play a positive role in regulating precocial feeding behavior in newly hatched chicks.     

Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors

D-amphetamine is known to induce an increase in dopamine release in subcortical structures, thus inducing locomotor hyperactivity in rodents. Previous data have indicated that only 15% of the D-amphetamine-induced release of dopamine in the nucleus accumbens is related to locomotor activity and that this 'functional' dopamine release is controlled by alpha1b-adrenergic receptors located in the prefrontal cortex. We show here that SR46349B (0.5 mg/kg, 30 min before D-amphetamine), a specific serotonin2A (5-HT(2A)) antagonist, can completely block 0.75 mg/kg D-amphetamine-induced locomotor activity without decreasing D-amphetamine-induced extracellular dopamine levels in the nucleus accumbens. Using the same experimental paradigm as before, i.e. a systemic injection of D-amphetamine accompanied by a continuous local perfusion of 3 microM D-amphetamine, we find that SR46349B (0.5 mg/kg) blocks completely the systemic (0.75 mg/kg) D-amphetamine-induced functional dopamine release in the nucleus accumbens. Finally, the bilateral injection of SR46349B (500 pmol/side) into the ventral tegmental area blocked both the D-amphetamine-induced locomotor activity and functional dopamine release in the nucleus accumbens, whereas bilateral injection of SR46349B into the medial prefrontal cortex was ineffective. We propose that 5-HT(2A) and alpha1b-adrenergic receptors control a common neural pathway responsible for the release of dopamine in the nucleus accumbens by psychostimulants.     

Stimulatory effect of n-octanoylated ghrelin on locomotor activity in the goldfish, Carassius auratus

Ghrelin is implicated in growth and feeding regulation in fish. The influence of ghrelin on behavior has not been well studied and the physiological role of des-fatty acid modification of this peptide is unclear. Therefore, the effects of intracerebroventricular (ICV) and intraperitoneal (IP) administration of synthetic n-octanoylated (acyl) goldfish ghrelin and des-n-octanoylated (des-acyl) ghrelin on locomotor and orexigenic activity in the goldfish were examined. ICV administration of acyl ghrelin at doses of 1 and 2 pmol/g body weight (BW) and IP administration at 16 pmol/g BW both induced significant increases in locomotor activity during for 45-60 min after treatment. Cumulative food intake was significantly increased by ICV injection of acyl ghrelin at doses of 1 and 2 pmol/g BW and IP injection at 8 and 16 pmol/g BW during the 60-min post-treatment observation period. In contrast, ICV and IP administration of des-acyl ghrelin produced no changes in locomotor and orexigenic activity. We also analyzed fasting-induced changes in the expression of ghrelin mRNA in the brain and intestine using a real-time PCR method. The level of ghrelin mRNA in the intestine, but not in the brain, obtained from fish fasted for 7 days was significantly higher than that in fish that had been fed normally. These results suggest that, in the goldfish, acyl ghrelin, but not des-acyl ghrelin, stimulates locomotor activity and enhances food intake via central and peripheral pathways.     

L-tryptophan attenuation of the dopaminergic and behavioral responses to cocaine.

This study assessed the effects of acute intravenous L-tryptophan (neutral amino acid precursor for serotonin) administration on cocaine-induced dopaminergic responses. Male Sprague-Dawley rats were surgically implanted with guide cannulas in the nucleus accumbens 5 days prior to the study and with vascular catheters (carotid artery and jugular vein) on the day prior to the study. Using microdialysis, extracellular nucleus accumbens dopamine levels were measured in freely moving rats. Following a 2 h equilibration period, animals were randomized (n=7-8 per group) to receive either a constant intravenous (IV) infusion of L-tryptophan (200 mg/kg/h) or an equal volume (2 ml/h) of saline. Ninety minutes into the infusion, cocaine (20 mg/kg) was injected intra-peritoneally. Cocaine increased nucleus accumbens microdialysate dopamine levels (500% at 30 min). This was associated with marked hyperactivity. Tryptophan infusion elevated plasma tryptophan (8-fold), and blunted the cocaine-induced increase in nucleus accumbens microdialysate dopamine levels by approximately 60%. Furthermore, tryptophan attenuated the cocaine-induced locomotor activity. These neurochemical and behavioral effects of tryptophan were associated with a marked increase in brain tissue serotonin content. The results of these studies demonstrate the feasibility of acute dietary manipulation of neurochemical and behavioral responses to cocaine. The duration, adaptation and tolerance to these effects remain to be elucidated.     

A selective orexin-1 receptor antagonist reduces food consumption in male and female rats

A variety of evidence implicates the orexins, especially orexin-A, in the regulation of food intake, but it has not been established whether this effect is mediated by the orexin-1 or orexin-2 receptor. In the present study, a selective orexin-1 receptor antagonist, 1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl urea hydrochloride (SB-334867-A), was administered intraperitoneally to rats under various conditions, and food consumption was subsequently measured over 24 h. In male rats, a single dose of SB-334867-A (30 mg/kg, i.p.) given during the light phase reduced both orexin-A-induced food intake (7 nmol, i.c.v.) and feeding stimulated by an overnight fast for 4 h. When given at the start of the dark phase, food consumption was reduced in both male and female rats over 24 h. Daily injections at the start of the dark phase for 3 days reduced natural feeding in male rats over 24 h on days one and three. These findings demonstrate direct inhibition of orexin-A induced food intake with a selective orexin-1 receptor antagonist. Furthermore, the suppression of nocturnal feeding and food intake stimulated by an overnight fast supports other evidence that orexin-A is involved in the regulation of natural feeding and suggests that orexin-1 receptor antagonists could be useful in the treatment of obesity.     

Meal-contingent intestinal lymph sampling from awake, unrestrained rats

Standard procedures for intestinal lymph collection involve continuous, quantitative drainage of the lymph fluid in anesthetized or restrained animals that are often euthanized within 48 h. We here describe a novel technique for the nonocclusive cannulation of the major intestinal lymph duct in rats that allows for repetitive in vivo sampling of intestinal lymph from unrestrained, awake, and ad libitum-fed animals. The distinctive feature of this novel technique is that a 5- to 7-mm long piece of Vialon tubing (OD/ID: 0.8/0.7 mm) with a small hole in its wall is first implanted into the major intestinal lymph duct for stabilization. The tapered tip (OD: ≈0.1 mm) of the catheter is then inserted into the hole of the tubing and fixed in place with a polyamid suture and a drop of tissue glue. In our hands, catheters implanted this way remain patent for up to 6 wk after surgery. In an initial experiment we collected lymph from six adult rats before (0) and 15, 30, 45, 60, 75, 90, 120, and 180 min (120 μl, each) after the onset of isocaloric (12.5 kcal) low-fat (LF) or high-fat (HF) test meals and measured active glucagon-like peptide-1 (GLP-1). Intestinal lymphatic GLP-1 concentration increased (P < 0.05) from ≈4 pmol/l (0 min) to a peak of 33 ± 6 (means ± SE) or 22 ± 4 pmol/l at 15 (HF) or 30 min (LF) after meal onset and gradually returned to baseline levels by 180 min. With this new technique fewer animals are required to generate physiologically relevant data for various aspects of gastrointestinal physiology that involve the lymphatic system. Furthermore, the advantage of this system is that the animal can act as its own control when the effect of different experimental protocols is tested.     

Role of medial prefrontal cortex dopamine in age differences in response to amphetamine in rats: Locomotor activity after intra-mPFC injections of dopaminergic ligands

Changes in medial prefrontal cortex (mPFC) dopamine receptor expression and in mPFC projections to the nucleus accumbens in adolescence suggest that there may be age differences in the regulation of drug‐related behavior by the mPFC. The age‐specific role of prelimbic D1 dopamine receptors on amphetamine‐induced locomotor activity was investigated. In experiment 1, rats aged postnatal day 30 (P30), P45, and P75, corresponding to early and late adolescence and adulthood, were given an injection of D1 and D2 antagonists into the prelimbic mPFC before a systemic injection of 1.5 mg/kg of amphetamine and locomotor activity was recorded. In experiment 2, effects of intra‐prelimbic injections of a D1 agonist and antagonist on locomotor activity produced by a lower dose (0.5 mg/kg) of amphetamine were investigated. D2 receptor antagonist did not alter amphetamine‐induced activity, whereas the D1 receptor antagonist reduced activity produced by 1.5 mg/kg of amphetamine more in P30 than in P45 and P75 rats. In addition, D1 agonist enhanced the locomotor activating effects of 0.5 mg/kg of amphetamine in adolescent rats and decreased activity in adult rats. These results suggest that insufficient activation of mPFC D1 receptors may underlie the reduced activity at the low dose of amphetamine in early adolescent compared to adult rats. © 2011 Wiley Periodicals, Inc. Develop Neurobiol, 2012